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Background: The accumulation, aggregation and deposition of amyloid-β (Aβ) peptides in the brain are central to
the pathogenesis of Alzheimer’s disease (AD). Alzheimer’s disease risk increases significantly in individuals carrying
one or two copies of APOE ε4 allele compared to individuals with an ε3/ε3 genotype. Growing evidence has
demonstrated that apolipoprotein E (apoE) strongly influences AD pathogenesis by controlling Aβ aggregation and
metabolism. Heparan sulphate proteoglycans (HSPGs) are abundant cell surface molecules that bind to both apoE
and Aβ. HSPGs have been associated with Aβ aggregation and deposition. Although several lines of research have
shown that apoE influences Aβ clearance in the brain, it is not clear how apoE influences HSPG-mediated cellular
uptake of Aβ.
Results: In this study, we show that apoE lipoprotein particles from conditioned media of immortalized astrocytes
isolated from human APOE-targeted replacement (TR) mice significantly suppress cellular Aβ42 and Aβ40 uptake
through cell surface HSPG. ApoE3 and apoE4 particles have similar binding affinity to heparin, while apoE4 particles
are likely hypolipidated compared to apoE particles. We also found that the apoE particles antagonize Aβ binding
to cell surface, and inhibited Aβ uptake in a concentration-dependent manner in Chinese hamster ovary (CHO)
cells. While the effect was not apoE isoform-dependent, the suppressive effect of apoE particles on Aβ uptake was
not observed in HSPG-deficient CHO cells. We further demonstrated that apoE particles reduced the internalization
of Aβ in mouse primary neurons, an effect that is eliminated by the presence of heparin.
Conclusions: Taken together, our findings indicate that apoE particles irrespective of isoform inhibit HSPG-
dependent cellular Aβ uptake. Modulating the ability of apoE particles to affect Aβ cellular uptake may hold
promises for developing new strategies for AD therapy.
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The accumulation and deposition of amyloid-β (Aβ)
peptides composed of 40 or 42 amino acids in the brain
are thought to be central events in the pathogenesis of
Alzheimer’s disease (AD) [1–4], the most common form
of neurodegenerative dementia in the elderly [5]. The
interaction of soluble Aβ forms, in particular oligomers,
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dysfunction [6]. On the other hand, neurons can also
internalize and efficiently degrade toxic species of Aβ
and eliminate these from the brain [7]. Thus, it is critical
to understand how Aβ interacts with cell surface receptors
and how these events impact Aβ aggregation, toxicity
and/or metabolism.
The ε4 allele of the APOE gene encoding the apolipo-
protein E (apoE) protein strongly influences AD risk and
age of onset [8, 9]; risk increases significantly in individ-
uals carrying one copy (ε2/ε4, OR 2.6; ε3/ε4, OR 3.2) or
two copies (ε4/ε4, OR 14.9) of the ε4 allele compared toistributed under the terms of the Creative Commons Attribution 4.0 International
by/4.0/), which permits unrestricted use, distribution, and reproduction in any
t to the original author(s) and the source, provide a link to the Creative
re made. The Creative Commons Public Domain Dedication waiver (http://
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Fig. 1 Characterization of astrocyte-secreted apoE particles.
Immunoaffinity purified apoE3 (500 ng) and apoE4 particles (500 ng)
were analyzed by non-denaturing gradient gel electrophoresis
(4–20 %) (a) and SDS-PAGE (b) followed by Western blot for apoE.
Numbers on the left are molecular size markers expressed in kDa.
c Total cholesterol concentrations of apoE3 and apoE4 particles were
measured using the Amplex Red cholesterol assay kit and normalized
against apoE concentrations. Data represent mean ± S.D. (n = 3).
***, p < 0.001
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the occurrence of cortical Aβ deposition is increased
already at early middle-age in asymptomatic APOE ε4
carriers [12, 13] and an age-dependent increase in Aβ
deposition in the brains has been proposed as a patho-
biological phenotype of APOE ε4 [14]. While apoE plays
a critical function in lipid transport in the brain [15],
apoE also directly or indirectly influences Aβ aggrega-
tion, cellular uptake, and metabolism [16, 17]. For ex-
ample, apoE was shown to protect primary human
pericytes and astrocytes from toxicity induced by Aβ40
harboring the Dutch mutation [18]. Cellular uptake of
oligomeric versus fibrillar forms of Aβ42 is also altered
by apoE in cultures of primary human astrocytes and
microglia [19, 20]. Whether an apoE-mediated reduction
in Aβ-uptake is beneficial or harmful is not clear; how-
ever, co-administration of apoE and Aβ42 increased the
gene expression of the Aβ-degrading enzyme neprilysin
in primary astrocytes isolated from post-mortem brain
tissue from non-demented subjects [21]. Despite these
pieces of evidence, whether interaction between apoE
and Aβ represents a major pathway under physiological
or pathophysiological conditions is not fully understood.
Previous studies have suggested that apoE forms com-
plexes with Aβ [6, 9] via both the receptor-binding
region in the N-terminal domain and the lipid-binding
region in the C-terminal domain [9, 22]. Interestingly,
these Aβ-binding regions within apoE overlap with the
heparin-binding regions [23, 24]. Of note, epitope map-
ping reveals that residues 13–17 in Aβ are common sites
that interact with both apoE and heparin [22, 25]. How-
ever, a recent report showed that only a small portion of
Aβ interacts with apoE lipoprotein particles in solution
under physiological conditions [26]. The same study also
reported the ability of apoE lipoprotein particles to
compete with Aβ for cellular uptake via the low-density
lipoprotein receptor-related protein 1 (LRP1) in astro-
cytes. Importantly, increasing the lipidation of apoE4
was recently suggested to alleviate cognitive impairment
and Aβ42 accumulation in APOE4-targeted replacement
(TR) mice suggesting that lipidation of apoE4 is key to
its pathophysiological properties [27].
In the brain, the major apoE receptors are the low-
density lipoprotein receptor (LDLR) [28] and LDLR-
related protein 1 (LRP1) [29, 30]. In addition, heparan
sulphate proteoglycan (HSPG) on the cell surface also
mediates cellular uptake of apoE lipoprotein particles, ei-
ther independently or in coordination with LRP1 [31].
Heparan sulphate proteoglycan is abundantly expressed
on the cell surface and functions as a receptor that inter-
acts with a variety of ligands through electrostatic inter-
actions [32]. In conjunction with LRP1, HSPG plays an
important role in neuronal cellular uptake of Aβ, which
also possesses a heparin-binding region [25, 33]. HSPGcontrols the entry of a variety of molecules on the cell sur-
face, including tau, α-synuclein and soluble APP [34, 35].
In this study, we aimed to elucidate whether the previ-
ously reported apoE-mediated decrease in cellular Aβ-
binding and uptake is orchestrated through competition
between apoE and Aβ for HSPG binding. We further
aimed to clarify if such an interaction is apoE isoform-
dependent. For these purposes we used immortalized
astrocyte-produced human apoE3 and apoE4 lipoprotein
particles, Chinese hamster ovary (CHO) cells, with or
without HSPG, and primary cultured neurons. We show
that apoE3 and apoE4 particles in a similar way irre-
spective of lipidation status compete with cellular Aβ
binding and uptake in a manner that depends on cell
surface HSPG.
Results
Astrocyte-secreted apoE3 particles carry more lipids than
apoE4 particles
Western blot of apoE3 and apoE4 after separation by
nondenaturing gel revealed high molecular weight parti-
cles (>232 kDa) in both the apoE3 and apoE4 prepara-
tions with a slightly higher presence of higher molecular
weight particles (>669 kDa) in the apoE3 preparation
(Fig. 1a). Upon separation of apoE3 and apoE4 under re-
ducing conditions, both apoE3 and apoE4 were detected
at the expected molecular size of monomeric apoE
(~37 kDa) (Fig. 1b). Employing a total cholesterol quan-
tification assay, the total cholesterol levels in the apoE3
particle preparation was found to be 1.61 ± 0.12 μg chol-
esterol/μg apoE, whereas the apoE4 particle preparation
contained 0.53 ± 0.13 μg cholesterol/μg apoE (Fig. 1c).
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particles secreted by primary astrocytes from apoE-TR
mice (Additional file 1: Figure S1). Together, these results
indicate that apoE produced by astrocytes exists as
lipoprotein particles with apoE3 particles carrying more
cholesterol compared to apoE4 particles.
ApoE binds to heparin and requires HSPG for cell
internalization
To determine whether immortalized astrocyte-produced
apoE particles bind to heparin, we injected purified
apoE3 and apoE4 particles into a Hitrap heparin HP
column attached to FPLC and eluted apoE with a linear
gradient of increasing concentrations of NaCl. The con-
centration of apoE in each fraction was quantified by
ELISA. ApoE3 particles and apoE4 particles bound to
heparin column and were effectively eluted with NaCl.
The peaks of both apoE isoforms were detected after
elution with a supraphysiological NaCl concentration of
0.45 M, which showed similar patterns with no obvious
difference in the elution profiles between apoE3 and
apoE4 particles (Fig. 2a). These results suggest that apoEFig. 2 ApoE particles bind to heparin and cell surface HSPG. ApoE3
particles (3.4 μg) and apoE4 particles (3.4 μg) were applied to HiTrap
Heparin HP columns attached to a FPLC and eluted with a linear salt
gradient (0–1.0 M NaCl). Concentrations of apoE in each fraction
were determined by ELISA (a). An average of n = 3 experiments are
plotted in the graph. CHO-K1 or CHO-M1 cells were incubated with
apoE3 (200 nM) (b) or apoE4 (200 nM) (c) for 18 h at 37 °C.
Internalization of apoE was analyzed by ELISA. Data represent mean
± S.D. (n = 3). **, p < 0.01; ***, p < 0.001particles, independent of isoform, strongly interact with
heparin at NaCl concentrations <0.45 M and thus apoE
likely binds to cell surface HSPG under physiological
conditions. Furthermore, to determine the kinetics of
apoE-heparin binding, their binding affinity was analyzed
by dot blot. The dissociation constant (Kd) value between
apoE3 particles and heparin was calculated as ~201 nM
(Additional file 2: Figure S2).
To further confirm the role of HSPG in apoE cellular
uptake, we used wild-type CHO-K1 cells and CHO-M1
cells lacking N-acetylglucosaminyltransferase/glucuro-
nyltransferase, which is required for the biosynthesis of
heparan sulphate [36]. When CHO-K1 or CHO-M1 cells
were incubated with apoE3 or apoE4 particles (200 nM)
for 18 h, the amounts of cell-associated apoE were 62 %
(Fig. 2b) and 71 % (Fig. 2c) lower in CHO-M1 cells than
those of CHO-K1 cells. These results indicate that
HSPG is a major receptor facilitating the cellular uptake
of astrocyte-secreted apoE particles in CHO cells.
ApoE particles compete with Aβ for internalization
through HSPG
To investigate effects of apoE on cellular Aβ uptake, CHO
cells were incubated with 50 nM of Aβ40 or Aβ42 in the
presence or absence of apoE particles for 18 h at 37 °C.
The amount of cell-associated Aβ was assessed by ELISA.
We found that the amounts of Aβ40 (Fig. 3a) and Aβ42
(Fig. 3b) were significantly reduced by both apoE3 and
apoE4 particles (200 nM) in CHO-K1 cells. The internal-
ization of both Aβ42 and Aβ40 in CHO-M1 cells was sig-
nificantly lower than in CHO-K1 cells, consistent with a
role of cell surface HSPG in cellular Aβ uptake [33]. More
importantly, the effects of apoE particles on cellular Aβ
uptake were completely abolished in CHO-M1 cells. To
further interrogate the effects of apoE particles on cellular
Aβ uptake, we performed a competition assay using fixed
concentration of Aβ42 (50 nM) and increasing concentra-
tions of apoE particles (0.2 nM to 200 nM) in CHO cells.
Both apoE isoforms significantly suppressed Aβ42 intern-
alization in CHO-K1 cells in a concentration-dependent
manner (Fig. 4). These results indicate that apoE particles
compete with Aβ for cellular uptake in a manner that de-
pends on cell surface HSPG. We next investigated
whether apoE affects Aβ binding to cell surface HSPG.
CHO-K1 cells and CHO-M1 cells were incubated with
Aβ42 (50 nM) in the presence or absence of astrocyte-
secreted apoE (200 nM) at 4 °C for 3 h. When the amount
of cell-associated Aβ was analyzed by ELISA, approxi-
mately 1 % of the added Aβ was bound to the cells. We
found that both apoE3 and apoE4 particles in a similar
manner inhibited Aβ binding to the cell surface in CHO-
K1 cells. However, these effects were absent in CHO-M1
cells (Fig. 5), indicating that apoE particles reduce Aβ
binding to cell surface HSPG.
Fig. 3 ApoE particles inhibit Aβ cellular uptake through HSPG in CHO cells. CHO-K1 (wild-type) cells or CHO-M1 (HS-deficient) cells were incubated
with 50 nM Aβ40 (a) or 50 nM Aβ42 (b) in the presence or absence of apoE3 particle (200 nM) or apoE4 particle (200 nM) for 18 h at
37 °C. The amount of internalized Aβ was quantified by ELISA. Data represent mean ± S.D. (n = 3). **, p < 0.01
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Aβ in primary neurons
To determine whether the observed effects of apoE
particles on Aβ uptake are also relevant in neurons, we
analyzed the effects of apoE3 particles on Aβ uptake in
the presence or absence of heparin in mouse primary
cortical neurons, as there is no detectable difference
between apoE3 and apoE4 particles on Aβ uptake in
CHO-cells. Neurons were incubated with Aβ42 in the
presence or absence of apoE3 particles with or without
heparin to antagonize HSPG binding for 6 h at 37 °C
and analyzed by confocal microscopy (Fig. 6a). When
neuronal cell bodies were observed by confocal micros-
copy, internalized Aβ was mainly co-localized with a
lysosomal marker, LysoTracker. In the presence of apoE3
particles or heparin, Aβ42 internalization was reducedcompared to the controls (Fig. 5). The effect of apoE3
particles on Aβ uptake was not observed when heparin
was co-incubated (Fig. 5). Consistent with the results
from confocal microscopy, FACS revealed that apoE3
particles and heparin significantly suppressed cell-
associated Aβ42 levels. More importantly, the effects of
apoE3 particles on Aβ42 uptake were eliminated by hep-
arin (Fig. 6b). Together, these results indicate that apoE
particles inhibit neuronal Aβ42 uptake though their
binding to cell surface HSPG.
Discussion
Interaction of Aβ with the neuronal cell surface signifi-
cantly affects synaptic functions and may induce neur-
onal toxicity in AD pathogenesis [37, 38]. The binding of
Aβ to synapses alters the distribution and/or activities of
Fig. 4 ApoE particles inhibit HSPG-mediated cellular uptake of Aβ in
a concentration-dependent manner. CHO-K1 cells or CHO-M1 cells
were incubated with Aβ42 (50 nM), together with various concentrations
of apoE3 particles (0.2 nM to 200 nM) or apoE4 particles (0.2 nM
to 200 nM) for 18 h at 37 °C. The amount of internalized Aβ was
quantified by ELISA. Data represent mean ± S.D. (n = 3)
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(NMDA) receptors [39] and metabotropic glutamate
receptors (mGluR5) [40], leading to synapse deterioration
and impairment of learning and memory. Oligomeric Aβ
also binds to prion protein (PrPc), resulting in significant
synaptic dysfunction [41]. Cell-surface HPSG may be
heavily involved in these processes as HSPG mediates
binding and uptake of aggregated Aβ and monomeric Aβ
on the cell surface [33, 42, 43]. HSPGs are composed of a
core protein, several heparan sulphate [44] glycosamino-
glycan [44, 45] chains, and uronic acid [46]. Heparan
sulphate chains, which have a high negative charge,Fig. 5 ApoE particles suppress Aβ binding to HSPG on the cell
surface. CHO-K1 or CHO-M1 cells were incubated with Aβ42 (50 nM)
with or without apoE3 particles (200 nM) or apoE4 particles (200 nM)
for 3 h at 4 °C. Cell-bound Aβ42 was quantified by ELISA. Data
represent mean ± S.D. (n = 3). *, p < 0.05presumably interact with the binding sites in the pro-
tein with positive charges [46].
Receptor-mediated cellular uptake and subsequent
lysosomal degradation is an important pathway for Aβ
clearance [47]. For example, LRP1 regulates cellular Aβ
uptake in neurons [48] and vascular smooth muscle cells
[49], and the disturbances of this pathway exacerbates
amyloid pathology in amyloid mouse models. ApoE is
also likely to interact directly with LRP1 and competes
with Aβ in the cellular clearance process at their physio-
logical concentrations [26]. These observations support
previous findings that apoE may have a suppressive
effect from the perspective of cellular Aβ elimination by
inhibiting cellular Aβ clearance pathways in both rodent
astrocytes [26] and primary human astrocytes and
microglia [19, 20, 26]. Interestingly, the clearance of
soluble Aβ in brain interstitial fluid is significantly ac-
celerated in Apoe-KO mice [16] and decreased apoE
expression under haploinsufficiency also results in less
Aβ deposition in amyloid mouse models expressing
human apoE isoforms [50, 51]. Further, immunother-
apy for apoE also reduces Aβ accumulation in rodent
models [52, 53].
Although binding of Aβ to cell surface HSPG can lead
to its subsequent trafficking to lysosomes for degrad-
ation, there is also strong evidence that such interaction
can be harmful by promoting Aβ aggregation and oligo-
mer formation [54, 55]. Several studies have shown that
soluble Aβ oligomers injure synapses resulting in impair-
ment of cognitive function through direct binding, and
the levels of Aβ in the brain of AD patients are positively
associated with synaptic protein and cognitive decline
[44, 56, 57]. In these cases, inhibition of Aβ binding to
cell surface HSPG by apoE particles can be beneficial
by reducing the formation of harmful Aβ oligomers.
Mounting evidence has shown that the APOE ε4 allele
dramatically increases the risk for AD, where apoE4 con-
tributes to AD pathogenesis by both loss-of-function in
neuroprotection and gain-of-function in neurotoxicity
compared to apoE3 [47, 58]. Although isoform-dependent
effects were not detected in the current study, apoE parti-
cles blocked the internalization of Aβ in a concentration-
dependent manner. As apoE indeed could act as an
inducer of Aβ fibril formation with apoE4 exhibiting the
strongest fibril catalytic activity [59], apoE isoforms may
differently modulate Aβ aggregation status which influ-
ences Aβ proteolytic degradation, rather than affecting
cellular Aβ uptake. In addition, we found that our purified
apoE4 particles contained less cholesterol than apoE3 par-
ticles, which is consistent with earlier studies proposing
apoE4 as a less efficient lipid-carrier [27, 60]. Thus, the
less lipidation status of apoE4 may also be involved in the
exacerbated Aβ plaque accumulation through apoE4-
induced Aβ aggregation.
Fig. 6 ApoE particles decrease HSPG-mediated cellular uptake of Aβ in primary neurons. a Mouse primary cortical neurons were incubated with
FAM-Aβ42 (500 nM) with or without apoE3 particles (200 nM) in the presence or absence of heparin (15 U/ml) for 6 h at 37 °C and analyzed by
confocal microscopy. Left, middle, and right columns indicate Lysotracker, FAM-Aβ42, and merged images, respectively. b Internalization of Aβ
was quantified by FACS after incubation with FAM–Aβ42 (500 nM) for 6 h. Data represent mean ± S.D. (n = 3). N.S., not significant; **, p < 0.01;
***, p < 0.001
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with Aβ for HSPG binding and subsequent cellular up-
take in CHO cells and neurons. By applying apoE3 and
apoE4 to a heparin HiTrap column, we found that both
apoE3 and apoE4 bound tightly to heparin at physio-
logical NaCl concentrations (<0.45 M). Consistent with
our results, surface plasmon resonance failed to detect
significant differences between apoE isoforms for their
bindings to heparin [61]. Another study has also demon-
strated that there are no significant differences in rate
and equilibrium constants of binding among the lipi-
dated apoE isoforms to heparin [24]. Since apoE has
heparin binding sites in both the N-terminal and C-
terminal domains with binding motifs identical between
apoE3 and apoE4 [23, 24], it is not surprising that these
apoE isoforms have similar binding affinities to heparin.
Using dot blot, we also investigated whether the astrocyte-
secreted apoE3-heparin affinity constant was similar to
apoE-heparin binding constants previously reported for
recombinant and plasma-derived apoE [24, 61, 62]. We
estimated the Kd to be 201 nM which resembles the
apoE3-heparin constant reported by Libeu and colleagues
who found a Kd of 320 nM as determined by surface
plasmon resonance [62], however recombinant apoE was
reported to bind heparin with higher affinity than that we
determined in the current study [61].
Previously Aβ was proposed to bind and form stable
complexes with apoE [9, 63, 64]; however, under physio-
logical conditions only a small portion of Aβ, estimated
at less than 5 % of total Aβ, was found to interact with
apoE particles [26]. It was proposed that despite minimal
interaction between apoE and Aβ, these two players in
solution compete for cellular uptake by astrocytes. Con-
sistent with that report, we also found limited molecular
interaction between Aβ (50 nM) and apoE (200 nM) as
assessed using SEC under which Aβ and apoE eluted in
separate fractions when quantified by ELISA (Additional
file 3: Figure S3). These seemingly conflicting results in
regard to apoE-Aβ binding may be due to various studies
employing different conditions, such as the concentrations
of apoE and Aβ, their aggregation state and apoE lipida-
tion state. It has been shown that CSF concentrations of
apoE range between 2 and 7 μg/ml (~200 nM) [65, 66],
whereas the interstitial fluid concentrations of Aβ were
found to be up to ~2000 pg/ml (~0.5 nM) [67]. Although
the focal concentration of apoE and Aβ remain unclear in
particular in the synaptic region, our results suggest that
apoE does not or only minimally interact with Aβ under
our experimental conditions.
In humans, higher levels of apoE tissue concentrations
were previously shown to correlate with lower Aβ bur-
den in human brain homogenates [68] and increased
CSF apoE levels were associated with higher CSF Aβ42
levels indicative of lower Aβ plaque burden [66]. Indeed,increasing apoE by retinoid X receptor (RXR) and liver
X receptor (LXR) agonist has been shown to decrease
Aβ deposition in amyloid mouse models [69, 70]. We
also recently reported that retinoic acid (RA) isomers
including all-trans-RA, 9-cis-RA, and 13-cis-RA can in-
crease the astrocyte-secreted apoE level through the
RXR/retinoic acid receptor pathway and simultaneously
decreased the amount of cell-associated Aβ in immortal-
ized astrocytes [71]. Thus, the regulation of brain apoE
levels through these receptors likely contributes to Aβ
metabolism in AD pathogenesis.
Conclusions
Overall, our findings support previous reports showing
an inhibitory effect of apoE on cellular Aβ uptake and
further extend those results by demonstrating that both
apoE3 and apoE4 particles similarly reduce cellular Aβ
uptake through interactions with cell surface HSPG in
CHO cells and neurons. In addition, apoE lipidation sta-
tus may not contribute to its inhibitory effect on cellular
Aβ binding and uptake. Together these findings propose
potent effects of apoE on Aβ clearance possibly by inhi-
biting cellular uptake which may promote the keeping of
Aβ in the extracellular space readily available for proteo-
lytic degradation. The interaction between apoE and
HSPG may be critical to the development of AD path-
ology by modulating the extra- versus intracellular pools
of Aβ with down-stream effects on several AD-related
pathways. Our findings propose that modulating the inter-
action between apoE, Aβ and HSPG may be an attractive
target to be explored for AD therapy.
Methods
Reagents
5(6)-Carboxyfluorescein (FAM)-Aβ42, synthetic Aβ40, and
synthetic Aβ42 were purchased from AnaSpec (Fremont,
CA). LysoTracker Red was purchased from Invitrogen.
Heparin was purchased from Baxter Healthcare Corp.
(Round Lake, IL).
Preparation of apoE particles
Immortalized apoE astrocyte cell lines producing human
apoE3 or apoE4, kind gifts from Dr. David Holtzman
[72], were cultured in DMEM/F12 (Invitrogen) with
20 % fetal bovine serum (Gibco), 1 mM sodium pyru-
vate, 1x non-essential amino acids, 2 mM L-glutamine,
and 1 % penicillin/streptomycin (Invitrogen). This cell
line was generated from primary astrocytes derived from
human APOE-TR mice, in which human APOE gene is
knocked into the mouse Apoe locus. Cells were cultured
at 37 °C in humidified air containing 5 % CO2. For puri-
fication of apoE lipoprotein particles, WUE-4, a mouse
monoclonal antibody to human apoE [73], was coupled
to CNBr-activated Sepharose 4B (GE Healthcare) and
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[74]. ApoE lipoprotein particles were then purified from
conditioned serum-free media of immortalized astrocytes
by using apoE antibody columns as described [72].
Western blot
Samples were separated by electrophoresis on either a
nondenaturing 4–20 % polyacrylamide gradient gel or
on a 10 % sodium dodecyl sulfate (SDS)-polyacrylamide
gel (PAGE) as described [73], transferred to nitrocellu-
lose membrane, and probed with a monoclonal antibody
to human apoE (WUE-4) followed by an HRP-conjugated
secondary antibody. The immunoreactive proteins were de-
tected using enhanced chemiluminescence (ECL, Thermo)
with images obtained with the Fujifilm® LAS-4000 gel
imager.
Cholesterol assay
Total cholesterol contents of the apoE3 and apoE4 parti-
cles were quantified with the Amplex Red cholesterol
assay kit (Invitrogen) according to the manufacturer’s
protocol.
Heparin-apoE interaction by affinity chromatography
Binding of apoE lipoprotein particles to heparin was
assessed using a heparin column as described previously
[75]. In brief, a 1 ml HiTrap heparin HP column (GE
Healthcare) was attached to a fast protein liquid chro-
matography (FPLC) (GE Healthcare) and run at a flow
rate of 1 ml/min. 3.4 μg of apoE3 or apoE4 were loaded,
and the column was washed with 20 mM Tris–HCl,
pH 7.4 for 10 column volumes. Bound apoE was eluted
in the same buffer using a linear gradient of 0–1.0 M
NaCl.
Heparin-apoE interaction by dot-blot analysis
WUE-4 (mouse monoclonal anti-apoE antibody), normal
mouse IgG (Invitrogen), and heparin (Sigma-Aldrich)
were spotted onto a nitrocellulose membrane (Bio-Rad)
using dot blot manifold apparatus (GE Healthcare).
Membrane strips were then incubated with increasing
concentrations of astrocyte-produced apoE3 particles
overnight at 4 °C. ApoE bound to the membrane was
detected with biotin-conjugated goat anti-apoE (Meridian
Life Science) and Streptavidin secondary antibodies. Blots
were imaged and quantified using Odyssey Infrared Im-
aging System (LI-COR Biosciences). For determination of
binding affinity, the integrated infrared signal (K Count)
of each dot was analyzed using Prism (Graphpad).
Cell culture
Wild-type (K1) and HSPG-deficient (M1) Chinese ham-
ster ovary (CHO) cells were grown in Ham’s F-12 medium
containing 10 % fetal bovine serum (Gibco) and 1 %penicillin/streptomycin (Invitrogen). Primary cortical neu-
rons were isolated from 17 days old embryos of wild-type
C57BL/6 mice and grown in Neurobasal medium (Invitro-
gen) supplemented with 0.5 mM GlutaMax (Invitrogen),
and B27 (Invitrogen) [33, 76].
Primary astrocyte cultures
Primary astrocytes were prepared from new-born pups
(P1-P2) with apoE3-TR and apoE4-TR background. In
brief, the brain was removed from the skull and the
meninges were discarded. Subsequently, the cortices
were minced and incubated with 0.05 % trypsin at 37 °C
for 15 min. Enzyme-digested dissociated cells were tritu-
rated with astrocyte growth medium and centrifuged at
300 × g for 5 min. The cell pellet was resuspended in
fresh medium, passed through a 70-μm nylon mesh, and
centrifuged at 300 × g for 5 min. The cells were plated
on poly-D-lysine–coated 75-flask in the media, which
were changed every three days. Cells were grown until
confluence. Medium was collected and purified using
the same method described above.
Membrane protein extraction
Membrane protein was extracted according to the protocol
of Thermo Scientific Mem-PER Plus Membrane Protein
Extraction Kit. Briefly, 5 × 106 cells were suspended in the
growth media by scraping the cells off the surface of the
plate with a cell scraper. After centrifugation at 300 × g for
5 min, cell pellet was resuspended in 1.5 ml of Cell Wash
Solution, and centrifuged at 300 × g for 5 min. The pellet
was resuspended in 0.75 ml of Permeabilization Buffer, and
incubated for 10 min at 4 °C with constant mixing. After
centrifugation for 15 min at 16,000 × g, the pellet was
dissolved in 0.5 ml of Solubilization Buffer and incubated
at 4 °C for 30 min with constant mixing. Supernatant con-
taining solubilized membrane and membrane-associated
proteins was collected after centrifugation at 16,000 × g for
15 min at 4 °C, and used for Western Blot. Protein was
loaded after normalized with the level of Na+-K+-ATPase.
Level of LRP1 was analyzed in the membrane fractions iso-
lated from CHO-K1 and CHO-M1 cells (Additional file 4:
Figure S4).
Detection of cell-associated Aβ and apoE by ELISA
Cells were incubated with Aβ42 (50 nM) or Aβ40 (50 nM)
in the presence of various concentrations of apoE3 or
apoE4 (0.2-200 nM) in serum free medium for 18 h
at 37 °C, and harvested by incubating with trypsin for
5 min at 37 °C. After washing two times with PBS,
cells were dissolved in 5 M guanidine in 50 mM Tris–HCl
(pH 8.0). To quantify cellular internalization of human
Aβ42, Aβ42 was captured with mAb 2.1.3 antibody
followed by detection with HRP-conjugated Ab5 antibody
[76]. To determine human apoE concentrations, apoE was
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detected with biotin-conjugated goat anti-apoE antibody
(Meridian Life Science) and poly-HRP-conjugated strepta-
vidin (Fitzgerald) essentially as previously described [71].
To assess cell-bound Aβ, cells were incubated with Aβ42
(50 nM) with or without apoE3 particles (200 nM), or
apoE4 particles (200 nM), for 3 h at 4 °C in PBS with
1.5 % FBS after suspension by Cell Dissociation Solution.
After washing three times with PBS, cells were dissolved
in 5 M guanidine in 50 mM Tris–HCl (pH 8.0) The Aβ
concentration in the cell lysate was quantified by ELISA
and normalized by the protein concentration of the cell
lysate [33].Size-exclusion chromatography (SEC) to determine apoE-
Aβ interaction
Immunopurified apoE3 (200 nM) was incubated in
serum-free DMEM-F12 medium containing Aβ (50
nM) for 3 h. The sample was loaded on SEC by fast
protein liquid chromatography (FPLC) using tandem
Superose-6, 10/300 GL columns (GE Healthcare) in
phosphate buffer containing 50 mM sodium phos-
phate (pH 7.4), 150 mM NaCl, 1 mM EDTA, and 0.02 %
sodium azide [71]. To determine a potential association
between apoE and Aβ, the concentrations of both apoE
and Aβ in each fraction were determined by ELISA as
described above.Confocal imaging of neuronal Aβ uptake
Mouse primary cortical neurons were cultured on eight-
well chambered cover glasses (Nalge Nunc International,
Rochester, NY). After incubation with FAM-Aβ42 (500
nM) at 37 °C for 6 h, together with or without apoE3
particles (200 nM) in the presence or absence of heparin
(15 U/ml), fluorescence associated with Aβ was ob-
served by confocal laser-scanning fluorescence micros-
copy (model LSM510 invert; Carl Zeiss, Jena, Germany).
LysoTracker (50 nM; Invitrogen) was added to determine
lysosome-Aβ colocalization 30 min before confocal
imaging.Fluorescence-activated cell sorter-based Aβ internalization
assays
Mouse primary cortical neurons were incubated with
FAM-Aβ42 (500 nM), together with vehicle or apoE3
(200 nM) in the presence or absence of heparin at 37 °C
for 6 h. Cell-surface Aβ was removed using 0.25 %
trypsin/EDTA (Invitrogen), and cell-associated Aβ was
analyzed for fluorescence on a BD FACSCalibur (BD
Biosciences). Control cells without any exposure to
fluorescence were used to assess background fluores-
cence [33].Statistical analysis
All quantified data represent an average of triplicate
samples and were analyzed by either t-test or one-way
ANOVA with a Tukey’s posttest. Error bars represent
standard deviation and p <0.05 was considered significant.
Additional files
Additional file 1: Figure S1. ApoE particles secreted by primary
astrocytes from apoE-TR mice. (A) ApoE3 and apoE4 particles were
isolated from condition medium of primary astrocytes from apoE3-TR
and apoE4-TR mice using immunoaffinity column. The purified apoE3
(500 ng) and apoE4 particles (500 ng) were analyzed by non-denaturing
gradient gel electrophoresis (4–20 %) and SDS-PAGE, followed by Western
blot for apoE. (B) Total cholesterol concentrations of the apoE3 and apoE4
particles were measured using the Amplex Red cholesterol assay kit and
normalized against apoE concentrations. Data represent mean ± S.D. (n = 3).
**, p < 0.001. (TIF 213 kb)
Additional file 2: Figure S2. Binding affinity of heparin-apoE3
interaction. (A) Representative dot blot of heparin and apoE3 particles.
Heparin was spotted onto nitrocellulose membrane along with mouse
monoclonal anti-apoE antibody, WUE4, as a positive control and normal
mouse IgG as a background. Membrane strips were incubated with
increasing concentrations of apoE3 particles from immortalized astrocytes.
Membrane-bound apoE was then visualized by biotin-conjugate anti-apoE
antibody and infrared streptavidin secondary antibody. (B) Integrated
infrared signal intensities from each dot were obtained and the average
intensities from three independent experiments were plotted to acquire
binding affinity curve and the dissociation constant (Kd). (TIF 2432 kb)
Additional file 3: Figure S3. ApoE particles are minimally associated
with Aβ. Aβ was incubated without (A) or with apoE3 particles (B).
Samples were applied to SEC with tandem Superose-6 columns.
Concentrations of apoE and Aβ in each fraction were analyzed by ELISA.
Graphs are averaged from separate experiments (n = 3). (TIF 4171 kb)
Additional file 4: Figure S4. Similar LRP1 levels in the membrane
fractions of CHO-K1 cells and CHO-M1 cells. Membrane fractions isolated
from CHO-K1 and CHO-M1 cells were subjected to Western blot for LRP1
and Na-K-ATPase (A). The levels of LRP1 were normalized against those of
Na+-K+-ATPase and plotted in (B). Data represent mean ± S.D.
(n = 3). N.S., not significant. (TIF 63 kb)
Abbreviations
Aβ: amyloid-β; AD: Alzheimer’s disease; ApoE: apolipoprotein E;
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